These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 25138241)

  • 21. Firm- and drug-specific patterns of generic drug payments by US medicaid programs: 1991-2008.
    Kelton CM; Chang LV; Guo JJ; Yu Y; Berry EA; Bian B; Heaton PC
    Appl Health Econ Health Policy; 2014 Apr; 12(2):165-77. PubMed ID: 24550087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The market dynamics of generic medicines in the private sector of 19 low and middle income countries between 2001 and 2011: a descriptive time series analysis.
    Kaplan WA; Wirtz VJ; Stephens P
    PLoS One; 2013; 8(9):e74399. PubMed ID: 24098644
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Price comparison of high-cost originator medicines in European countries.
    Vogler S; Zimmermann N; Babar ZU
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patent indicators: a window to pharmaceutical market success.
    Guo Y; Hu Y; Zheng M; Wang Y
    Expert Opin Ther Pat; 2013 Jul; 23(7):765-71. PubMed ID: 23611022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved?
    Cameron A; Mantel-Teeuwisse AK; Leufkens HG; Laing RO
    Value Health; 2012; 15(5):664-73. PubMed ID: 22867775
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Generic medicines].
    Peláez de Loño J
    Rev Enferm; 1999 Dec; 22(12):836-43. PubMed ID: 10797771
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determinants of branded prescription medicine prices in OECD countries.
    Kanavos PG; Vandoros S
    Health Econ Policy Law; 2011 Jul; 6(3):337-67. PubMed ID: 21676345
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Off-patent drugs in Italy. A short-sighted view?
    Garattini L; Ghislandi S
    Eur J Health Econ; 2006 Mar; 7(1):79-83. PubMed ID: 16425040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of generic competition on the price of brand-name drugs.
    Lexchin J
    Health Policy; 2004 Apr; 68(1):47-54. PubMed ID: 15033552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Controlling medicine prices in Sudan: the challenge of the recently established medicines regulatory authority.
    Ali GK; Yahia Y
    East Mediterr Health J; 2012 Aug; 18(8):811-20. PubMed ID: 23057369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Competition and the Reference Pricing Scheme for pharmaceuticals.
    Ghislandi S
    J Health Econ; 2011 Dec; 30(6):1137-49. PubMed ID: 21937137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does increased use of generic medicines by elders in Belgium help to contain escalating health care budgets?
    Dylst P; Vulto A; Simoens S
    J Aging Soc Policy; 2014; 26(3):266-80. PubMed ID: 24716815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Portuguese generic medicines market: a policy analysis.
    Simoens S
    Pharm Pract (Granada); 2009 Apr; 7(2):74-80. PubMed ID: 25152781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of pharmaceutical tendering on prices and market concentration in South Africa over a 14-year period.
    Wouters OJ; Sandberg DM; Pillay A; Kanavos PG
    Soc Sci Med; 2019 Jan; 220():362-370. PubMed ID: 30513486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The diffusion of generics after patent expiry in Germany.
    Fischer KE; Stargardt T
    Eur J Health Econ; 2016 Nov; 17(8):1027-1040. PubMed ID: 26573841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of generic substitution on price competition in Finland.
    Aalto-Setälä V
    Eur J Health Econ; 2008 May; 9(2):185-91. PubMed ID: 17508226
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Market uptake of biologic and small-molecule--targeted oncology drugs in Europe.
    Obradovic M; Mrhar A; Kos M
    Clin Ther; 2009 Dec; 31(12):2940-52. PubMed ID: 20110034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolutions in both co-payment and generic market share for common medication in the Belgian reference pricing system.
    Fraeyman J; Verbelen M; Hens N; Van Hal G; De Loof H; Beutels P
    Appl Health Econ Health Policy; 2013 Oct; 11(5):543-52. PubMed ID: 24062144
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The UK pharmaceutical market. An overview.
    Towse A
    Pharmacoeconomics; 1996; 10 Suppl 2():14-25. PubMed ID: 10163432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.